Jost Wolfgang H, Angersbach Dieter
Department of Neurology, Deutsche Klinik für Diagnostik, Wiesbaden, Germany.
CNS Drug Rev. 2005 Autumn;11(3):253-72. doi: 10.1111/j.1527-3458.2005.tb00046.x.
Dopamine agonists have become indispensable in the treatment of Parkinson's disease. In every-day practice, however, the decision to select the best compound for an individual patient is rendered difficult because of the large number of substances available on the market. This review article provides a closer look at the experimental and clinical studies with ropinirole published so far. Ropinirole is a non-ergoline dopamine agonist which has been proven to be effective in both, monotherapy and combination therapy of idiopathic Parkinson's disease. In addition to ameliorating bradykinesia, rigor, and tremor, ropinirole facilitates the daily life and improves depressive moods of patients with Parkinson's disease. The long-term complications of levodopa are avoided, and problems commonly associated with levodopa treatment are reduced. Ropinirole appears to have a neuroprotective effect. In addition to Parkinson's disease, ropinirole has also been used successfully in the treatment of restless legs syndrome.
多巴胺激动剂在帕金森病的治疗中已变得不可或缺。然而，在日常实践中，由于市场上有大量可用药物，为个体患者选择最佳药物的决策变得困难。这篇综述文章更深入地探讨了迄今为止已发表的关于罗匹尼罗的实验和临床研究。罗匹尼罗是一种非麦角林类多巴胺激动剂，已被证明在特发性帕金森病的单药治疗和联合治疗中均有效。除了改善运动迟缓、僵硬和震颤外，罗匹尼罗还能方便帕金森病患者的日常生活并改善其抑郁情绪。它避免了左旋多巴的长期并发症，并减少了与左旋多巴治疗通常相关的问题。罗匹尼罗似乎具有神经保护作用。除帕金森病外，罗匹尼罗还成功用于治疗不宁腿综合征。
